Express Scripts to Drop Big Sellers From AbbVie, Gilead in 2019
- Pharmacy-benefit firm shuffles coverage plan amid price debate
- Both list prices and drugmaker rebates factor into the changes
Source: IPGGutenbergUKLtd/iStockphoto
This article is for subscribers only.
Express Scripts Holding Co. said it will drop 48 drugs next year from its closely watched lineup of covered therapies, including Gilead Sciences Inc.’s HIV treatment Atripla and AbbVie Inc.’s hot-selling Mavyret medicine for hepatitis C.
The drug-benefit manager also won’t cover Sanofi’s hemophilia treatment Eloctate next year, it said in a statement.